Efficacy and safety of sodium glycididazole for esophageal carcinoma chemoradiotherapy: a Metaanalysis

doi:10.3760/cma.j.issn.1673422X.2016.12.006

Abstract

Abstract: ObjectiveTo assess the efficacy and safety of chemoradiotherapy combined with sodium glycididazole (CMNa) for the patients with esophageal carcinoma by conducting a Metaanalysis. MethodsBy searching Chinese Biomedical Database, China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, PubMed, Cochrane Library and EMBase, we collected randomized clinical controlled studies (RCTs) of chemoradiotherapy combined with CMNa and control group without CMNa in the treatment of esophageal carcinoma. According to the inclusion and exclusion criteria, data extraction and quality assessment were done by two researchers independently. Metaanalysis was performed by using Revman 5.3. ResultsA totle of 4 RCTs involving 262 patients were included. The Metaanalysis results showed that chemoradiotherapy combined with CMNa group had better complete remission rate (OR＝2.09, 95%CI: 1.243.54, Z=2.76, P=0.006) and overall response rate (OR=2.75, 95%CI: 1.395.44, Z=2.90, P=0.004) than the control group, with significant differences. The 1year survival rates of the two groups were similar, with no significant difference (OR＝1.85, 95%CI: 0.943.64, Z=1.77, P=0.08). There were no significant differences in the incidence rates of adverse reactions such as gastrointestinal adverse reaction (OR=0.92, 95%CI: 0.491.70, Z=0.28, P=0.78), bone marrow suppression (OR=0.69, 95%CI: 0.391.19, Z=1.33, P=0.18), liver damage (OR=0.93, 95%CI: 0.481.79, Z=0.23, P=0.82), radioactive esophagitis (OR=1.07, 95%CI: 0.582.00, Z=0.22, P=0.82 ), radioactive pneumonia (OR=0.76, 95%CI: 0.291.98, Z=0.56, P=0.57) and radioactive skin lesion (OR=1.11, 95%CI: 0.512.43, Z=0.26, P=0.80). ConclusionIn the treatment of esophageal carcinoma, chemoradiotherapy combined with CMNa has a good shortterm effect, and does not increase the occurrence of adverse reactions.

Key words: Esophageal neoplasms, Radiationsensitizing agents, Metaanalysis, Chemoradiotherapy

LI Hui, LIU Jing, WU Dong-Wen, LIAO Meng-Ting, WU Wen-Yue, YANG Meng-Ling, YE Lin, SHI Shu-Peng, SHEN Liang-Fang. Efficacy and safety of sodium glycididazole for esophageal carcinoma chemoradiotherapy: a Metaanalysis[J]. Journal of International Oncology, 2016, 43(12): 904-910.

References

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87108. DOI: 10.3322/caac.21262. ［2］ Tang WR, Fang JY, Wu KS, et al. Epidemiological characteristics and prediction of esophageal cancer mortality in China from 1991 to 2012［J］. Asian Pac J Cancer Prev, 2014, 15(16): 69296934. ［3］ Kato H, Nakajima M. Treatments for esophageal cancer: a review［J］. Gen Thorac Cardiovasc Surg, 2013, 61(6): 330335. DOI: 10.1007/s1174801302460. ［4］ Ajani JA, Barthel JS, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers［J］. J Natl Compr Canc Netw, 2011, 9(8): 830887. ［5］ Almhanna K, Shridhar R, Meredith KL. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care?［J］. Cancer Control, 2013, 20(2): 8996. ［6］ Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated metaanalysis［J］. Lancet Oncol, 2011, 12(7): 681692. DOI: 10.1016/S14702045(11)701425. ［7］ Zeng YC, Wu R, Xu ZG, et al. Safety and radiationenhancing effect of sodium glycididazole in locoregionally advanced laryngeal cancers previously treated with platinumcontaining chemotherapy regimens: a preliminary report［J］. Cancer Radiother, 2010, 14(1): 5964. DOI: 10.1016/j.canrad.2009.06.022. ［8］鹿红, 赵迪, 于大海, 等. 甘氨双唑钠联合同期放化疗治疗局部中晚期食管癌的临床观察［J］. 临床肿瘤学杂志, 2014, 19(10): 921924. ［9］张红生. 甘氨双唑钠联合同步放化疗治疗局部中晚期食管癌临床分析［J］. 现代肿瘤医学, 2012, 20(1): 9193. DOI: 10.3969/j.issn.16724992.2012.01.30. ［10］赵兴, 周毛, 王立平, 等. 甘氨双唑钠增敏食管癌后程加速超分割放疗协同化疗的临床研究［J］. 实用肿瘤杂志, 2012, 27(4): 358361. DOI: 10.13267/j.cnki.syzlzz.2012.04.019. ［11］梁军, 韩春, 王凤英, 等. 注射用甘氨双唑钠在胸段食管鳞癌同步化放疗中增敏作用的多中心、随机双盲的Ⅱ期临床研究［J］. 癌症进展, 2011, 9(6): 699706. DOI: 10.3969/j.issn.16721535.2011.06.021. ［12］ Eisenhauer EA, Therasse P, Bogaerts J, et al, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)［J］. Eur J Cancer, 2009, 45(2): 228247. DOI: 10.1016/j.ejca.2008.10.026. ［13］ Hiratsuka S. Vasculogenensis, angiogenesis and special features of tumor blood vessels［J］. Front Biosci (Landmark Ed), 2011, 16: 14131427. ［14］ Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis［J］. Cell, 1996, 86(3): 353364. ［15］ Yeh JJ, Kim WY. Targeting tumor hypoxia with hypoxiaactivated prodrugs［J］. J Clin Oncol, 2015, 33(13): 15051508. DOI: 10.1200/JCO.2014.60.0759. ［16］ Xing L, Wu P, Sun X, et al. Improve the effect of radiation therapy for recurrent esophageal squamous cell carcinoma with sodium glycididazole［J］. Inter J Radia Oncol Biol Phys, 2014, 90(1): S802S803. DOI: http://dx.doi.org/10.1016/j.ijrobp.2014.05.2316. ［17］ Zeng YC, Wu R, Xing R, et al. Radiationenhancing effect of sodium glycididazole in patients suffering from nonsmall cell lung cancer with multiple brain metastases: a randomized, placebocontrolled study［J］. Cancer Radiother, 2016, 20(3): 187192. DOI: 10.1016/j.canrad.2016.02.008. ［18］ Liu MZ, He LR, Lu TX, et al. Effect of hypoxic radiosensitizer sodium glycididazole on longterm result of radiotherapy for nasopharyngeal carcinoma［J］. Zhonghua Zhong Liu Za Zhi, 2006, 28(12): 932937. ［19］ Zeng YC, Xing R, Zeng J, et al. Sodium glycididazole enhances the radiosensitivity of laryngeal cancer cells through downregulation of ATM signaling pathway［J］. Tumour Biol, 2015, 37(5): 58695878. DOI: 10.1007/s1327701542781. ［20］蒋俊, 权循凤, 张丽, 等. 放疗联合甘氨双唑钠增敏治疗食管鳞癌的Meta分析［J］. 中华临床医师杂志: 电子版, 2013, 7(13): 59935997. DOI: 10.3877/cma.j.issn.16740785.2013.13.122. ［21］罗和生, 蒙建超, 童强. 甘氨双唑钠对食管癌放射治疗增敏作用的Meta分析［J］. 临床消化病杂志, 2012, 24(4): 223227. DOI: 10.3870/lcxh.j.issn.1005541X.2012.04.10.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[4]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[5]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[6]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[7]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer. Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition） [J]. Journal of International Oncology, 2023, 50(7): 385-397.
[8]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[9]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.
[10]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun. Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases [J]. Journal of International Oncology, 2023, 50(3): 138-143.
[11]	Ji Shiyu, Zhang Mingxin, Xie Huahong, Bai Yuan, Wang Tong. Observation on the efficacy of different stents in the treatment of patients with advanced esophageal cancer [J]. Journal of International Oncology, 2023, 50(2): 76-81.
[12]	Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng. Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy [J]. Journal of International Oncology, 2023, 50(12): 745-750.
[13]	Ma Xueyan, Lu Lili, Sun Pengfei. Advances in the immune microenvironment in cervical cancer [J]. Journal of International Oncology, 2023, 50(1): 47-50.
[14]	Li Zhilei, Luo Jialin. Biological indexes for predicting sensitivity of preoperative concurrent chemoradiotherapy for locally advanced rectal cancer [J]. Journal of International Oncology, 2022, 49(9): 564-567.
[15]	Wu Puyuan, Qi Liang, Wang Tao, Shi Minke, Sun Yuwei, Wang Lifeng, Liu Baorui, Yan Jing, Ren Wei. Efficacy of postoperative radiotherapy based on modified clinical target volume according to high-frequency recurrence regions in patients with esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(8): 464-472.